Mar 29, 2011 by Brian Orelli, PhDMuch More Than a Generic LawsuitThe Supreme Court will decide generic-drug makers fate.
Mar 28, 2011 by Brian Orelli, PhDInvestors Jump for Yervoy!Approvability answered, but surprises subsist.
Mar 25, 2011 by Brian Orelli, PhDPfile Pfizer Under "Potential"Promising pancreatic cancer drug has potential.
Mar 25, 2011 by Brian Orelli, PhDTeva:P&G :: Peanut Butter:ChocolateTwo great tastes that taste great together.
Mar 24, 2011 by Brian Orelli, PhDIt's the Combo That Matters for GileadAlthough it's also nice to show individual quad-pill components are working.
Mar 23, 2011 by Brian Orelli, PhDEli Lilly: Great Plan, Poor ExecutionEli Lilly shuns large mergers, but hasn't produced drugs on its own.
Mar 23, 2011 by Brian Orelli, PhDIs XOMA a Bad News Buy?Maybe, but wait for the rest of the data first.
Mar 22, 2011 by Brian Orelli, PhDPharmas in the DoghouseMerck and Sanofi call off their joint venture.
Mar 18, 2011 by Brian Orelli, PhDForget Getting Approved, for NowThe FDA wants more information on Eli Lilly's Amyvid.
Mar 17, 2011 by Brian Orelli, PhDTaking a Bite Out of Amylin's Obesity Drug PotentialIt's always about the safety.
Mar 17, 2011 by Brian Orelli, PhDEat or Be Eaten? Perhaps Both.Oft-rumored takeout target Human Genome Sciences goes shopping.
Mar 16, 2011 by Brian Orelli, PhDDifferent Name, Same Great ResultsIncyte and Novatis' ruxolitinib passes another clinical trial.
Mar 15, 2011 by Brian Orelli, PhDExtending the Competition in Parkinson's DiseaseImpax's extended-release drug looks good.
Mar 14, 2011 by Brian Orelli, PhDThis Deal Is No DogEli Lilly picks up Johnson & Johnson's European animal-health business.
Mar 11, 2011 by Brian Orelli, PhDSales Can Quadruple, More to ComeDendreon is still supply-constrained, but less than before.
Mar 11, 2011 by Brian Orelli, PhDJohnson & Johnson Gets a Slap on the WristThe consent decree could have been a lot worse.
